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Here we report corin, a synthetic hybrid agent derived from the class I HDAC inhibitor
(entinostat) and an LSD1 inhibitor (tranylcypromine analog). Enzymologic analysis reveals
that corin potently targets the CoREST complex and shows more sustained inhibition of
CoREST complex HDAC activity compared with entinostat. Cell-based experiments
demonstrate that corin exhibits a superior anti-proliferative profile against several melanoma
lines and cutaneous squamous cell carcinoma lines compared to its parent monofunctional
inhibitors but is less toxic to melanocytes and keratinocytes. CoREST knockdown, gene
expression, and ChIP studies suggest that corin’s favorable pharmacologic effects may rely on
an intact CoREST complex. Corin was also effective in slowing tumor growth in a melanoma
mouse xenograft model. These studies highlight the promise of a new class of two-pronged
hybrid agents that may show preferential targeting of particular epigenetic regulatory com-
plexes and offer unique therapeutic opportunities.
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Epigenetic regulation of gene expression by histone mod-ification has emerged as a major facet of physiologic anddisease processes. As a result, there has been intense interest
in developing epigenetic therapies leading to the discovery of
small molecule agents that target proteins involved in histone
modification1, 2. Several histone deacetylase (HDAC) inhibitors
like vorinastat and panobinostat (Fig. 1) are now approved drugs
for a specialized group of hematologic malignancies but not yet
for a wider range of cancer types including solid tumors3. One of
the conceptual challenges in targeting HDACs is that even
selective class I HDAC inhibitors such as entinostat (MS-275)
(Fig. 1) likely impact these deacetylase activities indiscriminately
across a range of distinct HDAC-containing multiprotein com-
plexes4, 5. Such broad cellular effects may result in a narrow
therapeutic window between disease efficacy and toxicity. Among
HDAC complexes, the CoREST complex, which includes HDAC1
or its close paralog HDAC2, the scaffolding protein CoREST, and
lysine specific demethylase 1 (LSD1) has attracted special inter-
est5, 6. The HDAC1/2 and LSD1 enzymatic activities within the
CoREST complex are commonly associated with silencing gene
expression and contribute to cancer and other diseases2, 3, 5.
Several classes of LSD1 demethylase inhibitors have been repor-
ted, and the best characterized are analogs of tranylcypromine
and phenelzine, established monoamine oxidase (MAO)
mechanism-based inactivators6–11 (Supplementary Fig. 1). These
MAO inhibitor analogs can be oxidized by LSD1’s active site
flavin cofactor (FAD) and converted to reactive electrophiles that
undergo covalent bond formation with FAD resulting in an
irreversible blockade of LSD18, 10, 12. These tranylcypromine and
phenelzine analogs have been shown to have anti-tumor potential
alone and in combination with HDAC inhibitors in preclinical
settings6–9.
We considered the possibility that dual action LSD1/HDAC
inhibitory compounds might be pharmaceutically advantageous.
By comprehensively blocking the CoREST complex, dual LSD1/
HDAC inhibitors could show a uniquely favorable profile of
pharmacologic action with an improved therapeutic window
relative to pure HDAC inhibitors. However, the challenges of
developing pharmacologically attractive dual action CoREST
inhibitors include: retaining high potency and specificity within
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Fig. 1 Strategy for combining the pharmacophores of clinically used HDAC inhibitors and a preclinical LSD1 inhibitor to generate dual action HDAC-LSD1
inhibitors. Blue—incorporated LSD1 inhibitor features, Green—incorporated HDAC inhibitor features, Orange—shared structural features, Black—features
not incorporated into dual inhibitors
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one compound for the two enzyme targets, achieving an
approximate balance in targeting LSD1 and HDAC1/2 in the
CoREST complex, and managing the size and polarity of such
hybrid compounds to have a favorable pharmacologic profile.
Results
Design and enzymatic analysis of dual LSD1/HDAC inhibitors.
Interestingly, compound 4SC-202 is proposed to act as a dual
HDAC/LSD1 inhibitor13. In our assays, we did not observe sig-
nificant inhibition of LSD1 with 4SC-202 (Supplementary Fig. 2)
so it would appear to have a different mechanism of action from
the inhibitors we report here (see below).
As a three-dimensional structure of the core CoREST complex
was not available to aid our design, we based our strategy on
current knowledge of pharmacophore characteristics of existing
unifunctional HDAC and LSD1 active site targeting compounds.
Inspection of several known HDAC and LSD1 inhibitor scaffolds
suggests that a common phenyl ring could serve as the central
element of an effective dual LSD1/HDAC inhibitor as shown
(Fig. 1). Thus, we designed and synthesized hybrid compounds
1–6 that contained standard HDAC zinc binding groups, a
benzamide (as in MS-275/entinostat) or a hydroxamic acid (as in
SAHA/vorinostat and LBH589/panobinostat), tethered to an
amine oxidase warhead, either phenelzine or tranylcypromine
(Fig. 1). Details of the synthetic routes, related to prior efforts on
related molecules, are shown in the Supplementary Methods.
Compound 7 was new to this study, but is the cyclopropylamine
analog of the established LSD1 inhibitor bizine7. We also
synthesized compounds 8 and 9 as controls that were closely
related to 6 and 2 respectively, but included subtle warhead
disruptions. Note that each of the designed bifunctional
compounds 1–6 have molecular weights (< 500 g mol−1) and
hydrophobicity (0.5< cLogP< 3) that are in the drug-like range
(Supplementary Table 1)14.
We proceeded to determine the potencies of each of the
designed hybrid compounds 1–6 against LSD1, as well as the
enzymatically related off-targets LSD2, and MAOs A and B.
These hybrid compounds 1–6 were quite potent LSD1 histone
demethylase inhibitors (Table 1), comparable to the parent
phenelzine and tranylcypromine analogs from which they were
derived. Each displayed time-dependent LSD1 inhibition suggest-
ing mechanism-based inactivation with kinact/Ki(inact) values that
were within 3-fold of the parent mono-targeted LSD1 blockers.
These compounds also showed moderate to strong selectivity
against MAO A, MAO B, and LSD2 (Table 1, Supplementary
Table 2, Supplementary Figs. 3–13). Hybrid compounds 1–6 were
also tested against HDAC1 and the hybrid analogs 1–4 and 6
showed submicromolar potency whereas analog 5 was weaker,
consistent with known structure-activity relationships related to
linker length (Table 1, Supplementary Fig. 14)15. Pan-HDAC
assays (HDACs 1–9) revealed that the benzamide compounds
1 and 2, analogs of class I HDAC inhibitor MS-275, were
> 100-fold selective for HDACs 1–3 as desired (Supplementary
Fig. 15)16, 17.
Corin shows sustained inhibition of the core CoREST complex.
As CoREST complexes contain HDAC1 or 2, and compound 2
lacks the metabolic liability of the hydrazine substituent18 found
in compound 1, we further examined the inhibitory properties of
the selective dual inhibitor 2, hereafter called corin, with the
purified core CoREST complex, prepared recombinantly from a
mammalian cell expression system (Table 2)19, 20. Size exclusion
chromatography revealed stable association of the ternary protein
complex and demonstrated 1:1:1 HDAC1:LSD1:CoREST1 stoi-
chiometry (Fig. 2a, Supplementary Fig. 16). Kinetic analysis of the
reconstituted CoREST complex HDAC1 component showed that
activity was linear with time and has kcat/Km values about 4-fold
greater than commercial isolated HDAC1 using the well-
established fluorescent peptide HDAC assay (Supplementary
Fig. 17a–c). For reasons that are not yet clear, the LSD1 activity
was observed to be bi-phasic, with an initial linear phase of 3–5
min (Supplementary Fig. 17d), and we consequently focused on
this first phase for inhibitor analysis. Under our experimental
conditions, corin and MS-275 were similary potent in blocking
CoREST complex HDAC1 activity, and corin matched the
potency of the tranylcypromine analog 7 and the clinical candi-
date GSK2879552 toward CoREST LSD1 demethylase activity
(Fig. 2b, c). Furthermore, corin was able to inhibit the deacety-
lation of semisynthetic, reconstituted nucleosomes by the CoR-
EST ternary complex (Fig. 2d).
To address the possibility that corin, because of its dual
warheads, might show sustained HDAC inhibition of the
CoREST complex compared to MS-275, we compared the HDAC
inhibitory properties of corin to that of MS-275 after prolonged
Table 1 Summary of inhibitor properties toward isolated LSD1, isolated HDAC1, and MAO A
isol. LSD1 MAO A isol. HDAC1
Cmpd ID kinact (min−1) Ki(inact) (µM) kinact/Ki(inact) (min−1 µM-1) kinact/Ki(inact) (min−1 µM−1) IC50 (µM)
1 0.28± 0.05 0.51± 0.16 0.55 0.055± 0.001 0.158± 0.003
2 (corin) 0.17± 0.03 0.10± 0.06 1.70 0.074 0.147± 0.007
3 0.20± 0.04 0.19± 0.06 1.05 ~0.06 0.156± 0.013
4 0.25± 0.06 0.39± 0.19 0.64 0.063± 0.003 0.090± 0.002
5 0.25± 0.07 0.27± 0.18 0.93 0.062± 0.004 1.34± 0.36
6 ND ND ~5 0.22 0.099± 0.003
bizinea 0.20± 0.05 0.15± 0.09 1.33 0.11± 0.11 > 30
GSK2879552b 0.28± 0.05 0.37± 0.19 0.76 ND –
7 0.17± 0.01 0.10± 0.02 1.70 0.37 > 30
8 ND ND ~5 0.24 > 30
9 ND > 20 ND ND 0.254± 0.014
MS-275 ND > 20 ND ND 0.233± 0.026
LBH589 ND > 20 ND ND ~0.003
SAHA ND > 20 ND ND 0.140± 0.013
LSD1= 110 nM, substrate= 300 µM dimethyl histone H3K41–21 peptide; HDAC1= 2.86 nM, substrate= 20 µM acetylated P53379–382 tetrapeptide RHKK(Ac); MAO A = 200 nM, substrate= 200 µM
tyramine
aMAO A inhibition data for bizine was reproduced from ref. 7
bDash marks indicate that compound was not evaluated in the corresponding assay. Data (mean± SEM) are representative of at least two independent experiments
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dialysis (Fig. 3a). We observed that 6 h after a 30 min exposure to
corin, the HDAC1 activity of the CoREST complex was markedly
reduced. In contrast, treatment of the CoREST complex with MS-
275 or MS-275 plus bizine led to little loss in HDAC1 activity. We
also carried out a parallel dialysis experiment after treatment with
corin and MS-275 of the HDAC1-containing MiDAC complex
(MIDEAS/DNTTIP1/HDAC1)4 that lacks an LSD1 subunit
(Fig. 3b). Both MS-275 and corin lacked inhibitory effects after
dialysis. These results suggest that corin’s sustained inhibition of
CoREST complex HDAC activity may be related to its LSD1
interaction. To further investigate the mechanism of inhibition of
the CoREST complex by corin, we performed a jump dilution
experiment (Fig. 3c). In this assay, after a 30 min exposure of 0.5
µM CoREST complex to 5 µM compound (corin, MS-275, LSD1
inhibitor 7, or desamino-corin 9), the mixtures were diluted 200-
fold and aliquots were removed at time points from 0 to 120 min
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Fig. 2 Dual inhibitors exhibit unique activity against the CoREST complex. a Coomassie stained gel depicting the three components of the CoREST ternary
complex after purification by size exclusion chromatography. b Dose response produced by inhibition of LSD1 as part of the CoREST complex by corin and
structurally matched compound 7. c Inhibition curves generated for corin and MS-275 against HDAC1 as part of the CoREST complex. d Corin inhibited the
deacetylation of reconstituted nucleosomes by the CoREST complex as determined by Western blot (CoREST complex= 100 nM, nucleosome= 100 nM).
Data (mean± SEM) are representative of at least two independent experiments
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Fig. 3 Corin exhibits sustained inhibition of CoREST complex HDAC activity. a Relative CoREST complex HDAC activity. b Relative MiDAC complex HDAC
activity. Protein complexes at 500 nM and all compounds at 5 µM preincubated for 30min prior to dialysis and dilution to measure HDAC activity at 2 nM
(CoREST complex) or 8 nM (MiDAC complex). 50 µM acetylated P53379–382 tetrapeptide (RHKK(Ac)) was used as substrate. c Corin exhibits near
irreversible inhibition of CoREST complex HDAC activity relative to unifunctional LSD1 and HDAC inhibitors after jump dilution (CoREST complex= 0.5
µM, inhibitor= 5 µM, substrate= 200 µM acetylated P53379–382 tetrapeptide RHKK(Ac)). dModel depicting dual engagement mechanism of corin leading
to sustained inhibition of CoREST complex HDAC activity. Data (mean± SEM) are representative of at least two independent experiments
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for measurement of HDAC1 activity. The jump dilution assays
confirmed that corin showed near irreversible inhibition of
HDAC1 activity whereas the HDAC1 activity with MS-275,
compound 7, compound 9, or a mixture of 7 and MS-275 was
restored within 40% of the vehicle rate by the end of the 2 h
period. The different inhibitory kinetics between compound 9
and corin are particularly notable since their chemical structures
are identical except for compound 9’s deletion of a nitrogen atom
which disables its LSD1 warhead.
These results are consistent with a mechanism of dual
engagement of the CoREST complex HDAC1 and LSD1 active
sites by corin’s warheads that can confer long-lasting enzyme
inhibition (Fig. 3d). The initial phase of inhibition in these kinetic
studies (Table 2) do not support enhanced potency of corin over
the mono-functional inhibitors, so it is unlikely that the active
sites of LSD1 and HDAC1 in the CoREST complex support dual
occupancy by corin in the baseline state. Interactions of one
enzyme active site with one warhead of corin may lead to a high
effective concentration of the second warhead for the other
enzyme subunit which over time induces conformational changes
in the protein complex facilitating concurrent engagement.
Computational modeling of the subunit proteins suggests the
plausibility of energetically stable conformations with surface
loop changes that allow for dual occupancy of LSD1 and HDAC1
by corin, but future studies will be needed to understand the
precise structural mechanisms behind corin’s inhibition of the
CoREST complex.
Anti-tumor properties of corin. Corin was subjected to an
NCI60 screen21, 22 which demonstrated preferential growth
inhibition of melanoma cells vs. other cancer cell lines, consistent
with the known epigenetic influences in the development and
progression of melanoma (Supplementary Fig. 18)23, 24. We
subsequently tested corin’s effects on malignant melanoma
WM983B histone modifications. Western blot and ELISA
revealed that corin stimulated global H3K9 acetylation
(H3K9Ac), as well as H3K4 mono- (H3K4Me1), di- (H3K4Me2),
and tri-methylation (H3K4Me3) (Fig. 4a, b, Supplementary
Fig. 19). In comparison to MS-275, corin appeared to more
potently (corin EC50 95 nM vs. MS-275 EC50 420 nM) and effi-
caciously induce cellular H3K9 acetylation. Although MS-275
lacks direct LSD1 inhibitory properties, its ability and that of
other HDAC inhibitors to influence global H3K4 methylation has
been noted previously, presumably resulting from indirect impact
on cellular methyltransferase or demethylase enzymes25, 26.
Notably, corin showed more powerful anti-proliferative action
against WM983B cells relative to MS-275 with an IC50 of ∼200
nM, about 12-fold lower than that of MS-275 (Fig. 4e and
Supplementary Fig. 20a, e). In fact, corin (1 µM) consistently
showed a greater anti-proliferative effect than MS-275 (1 µM)
across a panel of 10 melanoma cell lines (Fig. 4c). We also
observed that combining the monofunctional LSD1 inhibitor 7
(1 µM) along with MS-275 (1 µM) across these cell lines did not
match the anti-proliferative effect of corin (1 µM) suggesting that
the integration of the two inhibitory warheads in corin is critical
for its pharmacologic action. Consistent with this idea, desamino-
corin compound 9 with its LSD1 warhead disrupted has a less
potent IC50 of 5 µM, similar to that of MS-275 (Supplementary
Fig. 20b). Interestingly, corin (1 µM) was non-toxic to primary
human melanocytes in contrast to MS-275 (1 µM) (Fig. 4c).
To explore the possible role of the CoREST complex in
mediating the more powerful anti-proliferative action of corin vs.
MS-275 against WM983B cells, we used shRNA to stably
knockdown CoREST1, confirmed by qRT-PCR and Western blot
(Supplementary Fig. 20c, d). It was also observed that these
CoREST1 knockdown WM983B cells grew about 40% more
slowly relative to control WM983B cells, indicating the functional
importance of CoREST1 in WM983B cell proliferation (Fig. 4d).
We next performed a dose–response analysis of MS-275 and
corin in the parental vs. the CoREST1 knockdown WM983B cells.
Strikingly, knockdown of CoREST1 conferred a heightened
sensitivity to the anti-proliferative action of MS-275 in
WM983B cells, rendering a similar dose–response profile to that
of corin, whose antiproliferative effects were not altered by
CoREST1 knockdown (Fig. 4e, f, Supplementary Fig. 20e, f). In
contrast, knockdown in WM983B cells of the distinct corepressor
protein SIN3A which participates in an HDAC1 complex that
does not include LSD15 does not sensitize cells to MS-275 and the
selectivity margin between corin and MS-275 is maintained under
these conditions (Fig. 4g, h, Supplementary Fig. 21a).
We also investigated the comparative pharmacology of MS-275
and corin in HCT116 colon cancer cells and the isogenic LSD1−/−
HCT116 cell line27. As observed previously, LSD1−/− HCT116
cells show a diminished proliferation rate relative to the parental
HCT116 cells (Fig. 5a, Supplementary Fig. 21b). Loss of LSD1
enhanced the sensitivity of HCT116 cells to MS-275, but not
corin (Fig. 5b, c). Taken together with the CoREST1 and SIN3A
knockdown experiments, these results suggest that the more
powerful anti-proliferative action of corin vs. MS-275 in the
melanoma and colon cancer cells analyzed may involve its more
comprehensive targeting and sustained inhibition of the LSD1-
containing CoREST complex relative to other complexes. Never-
theless, even with CoREST1 knockdown, corin retains potency
suggesting it can also block class I HDACs in other contexts.
To further assess the mechanistic basis of corin vs. MS-275 in
WM983B cells, we analyzed cellular gene expression profiles after
24 h treatment with 2.5 µM of each compound. Approximately
1300 genes were selectively up-regulated at least 2-fold by corin
compared with MS-275 under these conditions (Fig. 5d, Supple-
mentary Fig. 22a). Gene ontology analysis suggested that genes
important for differentiation, as well as modulators of cell
motility were significantly up-regulated by corin compared to
MS-275 (Supplementary Table 3). In addition, a large number of
tumor suppressor genes were preferentially induced by corin,
many of which have been previously observed to be epigenetically
silenced in cancer (Fig. 5e, Supplementary Tables 4 and 5). We
examined several of these tumor suppressors by qRT-PCR
including p21, CHOP, SIK1, MXD1 and several others, each of
which showed dramatic increases after corin treatment vs. MS-
275 treatment, confirming the microarray data (Fig. 5f, g,
Supplementary Fig. 22b–m). As in the anti-proliferative findings,
Table 2 Biochemical characterization of dual inhibitors
against LSD1 and HDAC1 as part of the CoREST ternary
complex
Cmpd ID CoREST complex
(LSD1) IC50 (µM)
CoREST complex
(HDAC1) IC50 (µM)
1 1.8± 0.3 0.230± 0.014
2 (corin) 0.33± 0.05 0.206± 0.035
bizine 1.4± 0.6 ND
GSK2879552a 0.38± 0.01 –
7 0.36± 0.01 ND
9 > 20 0.328± 0.026
LSD1 assay: CoREST complex= 100 nM, substrate= 60 µM dimethyl histone H3K41–21 peptide;
HDAC1 assay: CoREST complex= 2 nM, substrate= 50 µM acetylated P53379–382 tetrapeptide
RHKK(Ac)
aDash marks indicate that compound was not evaluated in the corresponding assay. Data
(mean± SEM) are representative of at least two independent experiments
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none of these genes showed enhancement by combining MS-275
with compound 7, highlighting the pharmacologic advantage of
the hybrid molecule over the separate unifunctional compounds.
We also found that the preferential induction by corin vs. MS-275
of CHOP and MXD1 was abolished in the CoREST knockdown
melanoma cells (Supplementary Fig. 23a, b). Using ChIP-PCR
analysis, we observed that the promoter regions of the CHOP and
MXD1 genes showed high occupancy by both LSD1 and HDAC1
compared with control genes SYN1 and VAMP7 which were
not selectively induced by corin (Fig. 5h, i, Supplementary
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Figs. 22n, 23c, d, 24a, b). These data suggest that corin’s dual
targeting of LSD1 and HDAC1 in the CoREST complex may
contribute to its enhanced cellular pharmacology in melanoma.
The effects of LSD1 and HDAC inhibitors as well as corin were
also investigated with the primary human cutaneous squamous
cell carcinoma cell lines IC1 and MET1 (Table 3 and
Supplementary Figs. 25–27). In contrast to the melanoma lines
examined, we found that both of these cutaneous cancer lines
were quite sensitive to the potent monofunctional LSD1
inhibitors compound 7, GSK2879552, and to a lesser extent
tranylcypromine (Table 3, Supplementary Figs. 25 and 26) but
not to the MAO inhibitor pargyline which is devoid of LSD1
inhibitor activity28. We also found that the proliferation of IC1
and MET1 were more powerfully inhibited by corin than either
the LSD1 inhibitors or the mono-functional HDAC inhibitors
MS-275 and compound 9 (Table 3, Supplementary Figs. 25 and 26).
In the case of IC1 and MET1, the anti-proliferative effects of the
mono-functional LSD1 inhibitors compound 7 and GSK2879552
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Fig. 5 Analysis of gene knockout effects in HCT116 cells and gene expression changes in melanoma associated with corin treatment. a Knockout of LSD1 in
HCT116 cells decreased the rate of cancer cell proliferation by ~40% (n= 4). b, c Knockout of LSD1 enhanced the potency of MS-275 but did not affect the
potency of corin in HCT116 cells as determined by [3H]thymidine incorporation after 48 h treatment (n= 4). d, e Venn diagrams depicting increases in
global and tumor suppressor gene transcription (fold change≥ 2σ, p< 0.05), respectively, upon 2.5 µM MS-275 or corin treatment (n= 3). f, g qRT-PCR
validation of gene expression changes identified by microarray. WM983B melanoma cells were treated with inhibitor (2.5 µM) for 24 h prior to RNA
isolation and analysis (n= 3). h ChIP-PCR localized CoREST complex components HDAC1 and LSD1 to the promoter region of CHOP (n= 3). i ChIP-PCR
localized HDAC1, but not LSD1, to the promoter region of SYN1 (n= 3). Data (mean± SEM) are representative of at least three independent experiments
(unpaired t test, *p< 0.05, ***p< 0.001)
Table 3 Anti-proliferative effects of corin and related
compounds in cutaneous squamous cell carcinoma cells
after 72 h treatment
IC50± SE (µM)
Compound IC1 cells MET1 cells
Corin 0.041± 0.011 0.006± 0.001
MS-275 1.03± 0.07 0.144± 0.014
Compound 9 0.397± 0.042 0.094± 0.009
Compound 7 0.448± 0.187 0.171± 0.036
GSK2879552 2.91± 0.71 0.211± 0.042
MS-275 + Compound 7 0.249± 0.075 0.011± 0.001
MS-275 + GSK2879552 0.275± 0.027 0.042± 0.007
Tranylcypromine 3.94± 0.98 2.03± 0.54
Pargyline > 270 > 270
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were partially additive with MS-275 when used in combination.
But the IC50 of corin was still 5-fold and 2-fold lower in IC1 and
MET1, respectively, than the combination of compound 7 and
MS-275. Moreover, corin proved far less toxic to primary human
keratinocytes than MS-275, which were rather resistant to LSD1
inhibitors (Supplementary Fig. 28). These data highlight the
potential therapeutic advantage of the hybrid agent in cancer cells
that are particularly LSD1 inhibitor sensitive.
Pharmacologic analysis of corin using a mouse xenograft. We
next demonstrated that corin showed high metabolic stability in
human plasma, human liver microsomes, and mouse liver
microsomes (Supplementary Table 6), and was well-tolerated in
mice for 10 days of once daily intraperitoneal (IP) administration
of up to 30 mg kg−1 based on stable similar weight relative to
vehicle (Supplementary Fig. 29). We went on to examine the
ability of corin to impact tumor growth in a melanoma mouse
xenograft model using SK-MEL-5 cells. Melanoma xenografts of
SK-MEL-5 cells are well established29 and, importantly, corin
showed comparable efficacy (IC50 ~130 nM) in this cell line as
compared to WM983B cells (Supplementary Fig. 30). These
studies showed that corin treatment (30 mg kg−1, IP, every 24 h)
led to a 61% reduction in tumor volume after 28 days relative to
vehicle (Fig. 6a), with body weights and blood cell counts being
similar between the treated and control animals at the end of the
study (Supplementary Fig. 31). We attempted treatment of these
xenograft mice with the same dose and schedule of MS-275 but
this proved too toxic as 6 of 10 animals died with 1 week so this
arm was discontinued. Examination of the tumor tissue recovered
from mice treated with corin vs. vehicle showed that tumor cells
from the corin-treated animals displayed elevated H3K9 acet-
ylation, H3K4 dimethylation (Fig. 6b), and increased expression
of p21, CHOP, and MXD1 (Fig. 6c), consistent with the cell
culture experiments. Moreover, tumor cells from corin-treated
animals showed a reduction in the proliferation biomarker
Ki67 suggesting that the corin-treatment was blocking prolifera-
tion of these cells (Fig. 6d). These results substantiate corin’s
promise for in vivo anti-cancer applications.
Discussion
It is generally accepted that in the context of cancer, single agent/
single target therapeutics are poorly effective because of cancer
pathway redundancies and the emergence of drug resistance30.
Thus, many anti-neoplastic treatment protocols involve two or
more drugs to achieve synergistic efficacy and prevent clonal
resistance31, 32. An alternative strategy could involve the devel-
opment of one drug that has engineered multifaceted pharma-
codynamics. There have been several reports both in the context
of small molecules, as well as protein biologics to exploit and/or
rationally incorporate multi-target pharmacology in anti-tumor
agents33–35. Targeting two enzymes in the same complex that are
thought to work concertedly to epigenetically inactivate gene
expression offers an opportunity for synergistic pharmacology.
While bisubstrate analog inhibitors that bind bivalently to a single
enzyme that follows a ternary complex mechanism are com-
monplace36, dual action inhibitors aimed at two different
enzymes in a protein complex are not well-established; however,
these studies lend credence to the feasibility of this strategy. A
somewhat related bivalent approach targeting LSD1 and HDAC
was recently reported although the hybrid compound is designed
to split into LSD1 and HDAC inhibitor components after LSD1
inactivation and the CoREST complex targeting capability has not
yet been assessed37.
Our findings suggest that comprehensively targeting the CoR-
EST complex can enhance residence time and this is facilitated by
the hybrid functionality in corin vs. monofunctional HDAC inhi-
bitors. However, further genomic studies will be needed to provide
a full understanding of the relative targeting of the CoREST
complex by corin chromatin wide in cells. Regardless, our results
substantiate that such targeting can offer possible anti-tumor effi-
cacy in malignancies that are especially sensitive to LSD1 inhibitors
such as cutaneous squamous cell cancer, as well as those that are
resistant to such agents, as seen in melanoma. Beyond the potential
value of comprehensive epigenetic complex targeting and
enhanced residence time38, dual action inhibitors promote a bal-
ance in concomitant enzyme blockade at the single cell level and
overcome the substantial regulatory challenge of advancing two
separate compounds concurrently into clinical trials.
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Fig. 6 In vivo analysis of corin in a melanoma xenograft. a Daily IP administration of corin (30mg kg−1) potently inhibited tumor growth in an SK-MEL-5
melanoma cell mouse xenograft model over the course of a 28-day treatment regimen (n= 10 mice per condition). b Western blot depicting increases in
histone H3K4 methylation and H3K9 acetylation in tumor tissue obtained from the SK-MEL-5 melanoma xenograft. c Gene expression changes induced by
corin in mouse xenograft tumor tissue as determined by qRT-PCR. d Corin treatment decreased the expression of Ki67, a biomarker for cell proliferation, in
mouse xenograft tumor tissue (scale= 100 µm). Data (mean± SEM) are representative of at least two independent experiments (unpaired t test, **p<
0.01, ***p< 0.001)
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Methods
LSD1 expression and inhibition assay. LSD1 inhibition was determined using a
previously developed horseradish peroxidase (HRP) coupled assay. Briefly, LSD1
(residues 171–852) containing an N-terminal GST-tag was overexpressed in E. coli
and purified via affinity chromatography39. GST-LSD1 concentration was deter-
mined by gel electrophoresis (~0.9 mgml−1, ~8.8 µM) and aliquots were stored at
−80 °C (storage buffer: 280 mM NaCl, 5.4 mM KCl, 20 mM Na2HPO4, 3.6 mM
KH2PO4, 1 mM BME, 1 mM EDTA, 10% glycerol, pH 7.4). For each experiment, a
fresh aliquot was thawed and diluted with storage buffer (not containing BME) to
0.45 mgml−1 (4.4 µM) immediately before use. 60 µl reactions containing 50 mM
HEPES (pH 7.5), 0.1 mM 4-aminoantipyrine (4-AP), 1 mM 3,5-dichloro-6-
hydroxybenzensulfonate (DHBS), 300 µM diMeK4H31–21 substrate (ARTK
(Me)2QTARKSTGGKAPRKQLA, Km = 25 µM, kcat = 3 min−1)39, 0.04 mgml−1
(906 nM) HRP (Worthington Biochemical Corporation, LS002559), and varying
concentrations of inhibitor were initiated by the addition of LSD1 (final [LSD1] =
110 nM). Changes in absorbance at 515 nm were monitored over 20 min at 25 °C
using a Beckman Instruments DU series 600 spectrophotometer. Product forma-
tion was calculated using the Beer–Lambert law and an extinction coefficient of
26,000 M−1 cm−1 for the generated chromophore. Progress curves representing the
concentration of product formed over time were plotted and subjected to a series of
mathematical transformations to determine the kinetic parameters (kinact, Ki(inact))
for each compound7, 39. Inhibitor stocks were prepared in 8% DMSO/water by 2-
fold serial dilution (final concentration of DMSO in each reaction was 2%).
Reported kinetic parameters represent at least two independent experiments.
CoREST complex production and purification. Constructs of LSD1, HDAC1, and
FLAG-tagged CoREST1 were each cloned into a pcDNA 3.0-based vector and
transiently transfected into HEK293F suspension cells (Invitrogen) using branched
polyethylenimine (Sigma-Aldrich) and incubated for 48 h at 37 °C19, 20,]. Next, cells
were pelleted by centrifugation at 2860xg for 10 min and resuspended in cold lysis
buffer (50 mM Tris–HCl, pH 7.5, 50 mM KCl, 5% glycerol, 0.4% Triton X-100, 1X
Roche EDTA-free Complete Protease Inhibitor cocktail). The cells were lysed via
sonication (15 s on, 30 s off, 42% amplitude, 3 cycles) and insoluble fractions were
pelleted by centrifugation at 26,300xg for 20 min. The complex was initially pur-
ified via FLAG affinity chromatography by incubating the lysate with 1 ml of Anti-
FLAG M2 affinity gel (Sigma-Aldrich) per liter of cell culture at 4 °C for 30 min.
The resin was collected and washed with wash buffer (50 mM Tris–HCl, pH 7.5, 50
mM KCl, 5% glycerol) three times and then washed with cleavage buffer containing
reducing agent (50 mM Tris–HCl, pH 7.5, 50 mM KCl, 5% glycerol, 0.5 mM tris(2-
carboxyethyl)phosphine (TCEP)) three times to prepare for TEV protease cleavage.
The affinity gel was resuspended in cleavage buffer and incubated with TEV
protease (Invitrogen) overnight at 4 °C followed by concentration of the cleaved
complex. The complex was subsequently purified using Size Exclusion Chroma-
tography by loading onto a 25 ml Superose 6 10/300 GL column (GE Healthcare)
pre-equilibrated with buffer (50 mM Tris–HCl, pH 7.5, 50 mM KCl, 0.5 mM
TCEP) and run at 0.25 ml min−1. Fractions were checked for purity via SDS–PAGE
and concentrated. Complex concentration was determined via MicroBCA assay
(ThermoScientific) with BSA as the standard. The final complex was then stored at
4 °C. The complex was expressed in 1.2 L of culture and produced ~0.25–0.5 mg of
> 90% pure protein19. Complex is stable for ~2 weeks at 4 °C, do not freeze.
MiDAC ternary complex production and purification. The MiDAC complex
(MIDEAS, DNTTIP1, HDAC1) was expressed in HEK293F cells which were lysed
in 50 mM Tris–HCl, 100 mM potassium acetate, 10% (v/v) glycerol, 0.5% (v/v)
Triton X-100, pH 7.5 in the presence of 1× Roche Complete EDTA-free protease
inhibitor4. The complex was purified by FLAG-affinity chromatography and, after
washing, was eluted by TEV-protease cleavage and finally purified by gel filtration
on a Superdex-200 column (GE Healthcare)4.
CoREST complex (LSD1) inhibition assay. Inhibition of CoREST complex LSD1
activity was determined using the same coupled assay described for isolated LSD1
with the following modifications. The CoREST ternary complex (120 nM) was
incubated with varying inhibitor concentrations in the presence of 60 mM HEPES
(pH 7.4), 0.12 mgml−1 BSA, and 0.12 mM inositol hexakisphosphate for 5 min at
25 °C as a 50 µl reaction. After a 5 min preincubation, the coupling reagents 4-AP,
DHBS, and HRP were added and the reaction was initiated by the addition of
substrate. The final reaction volume was 60 µl and comprises 50 mM HEPES (pH
7.4), 0.1 mgml−1 BSA, 0.1 mM inositol hexakisphosphate, 0.1 mM 4-AP, 1 mM
DHBS, 60 µM diMeK4H31–21 substrate, 0.04 mgml−1 (906 nM) HRP, 100 nM
CoREST ternary complex, and varying concentrations of inhibitor. Inhibitory
parameters were determined by examining changes in absorbance over 5 min.
Reported kinetic parameters represent at least two independent experiments.
HDAC isoform inhibition assay. The inhibitory effect of compounds on
HDAC1–HDAC9 function was determined in vitro using an optimized homo-
genous assay performed in 384-well plate format16. In this assay, recombinant
HDAC protein (HDAC1 100 pg µl−1, HDAC2 200 pg µl−1, HDAC3 100 pg µl−1,
HDAC4 0.5 pg µl−1, HDAC5 10 pg µl−1, HDAC6 350 pg µl−1, HDAC7 2 pg µl−1,
HDAC8 16 pg µl−1, HDAC9 20 pg µl−1; BPS Bioscience) was incubated with
inhibitory compound for 3 h, and then fluorophore-conjugated substrates
MAZ1600 and MAZ1675 were added at a concentration equivalent to the substrate
Km (MAZ1600: 8.9 µM for HDAC1, 10.5 μM for HDAC2, 7.9 μM for HDAC3, and
9.4 μM for HDAC6. MAZ1675: 11.5 μM for HDAC4, 64.7 μM for HDAC5, 29.6
μM for HDAC7, 202.2 μM for HDAC8 and 44.3 μM for HDAC9). Reactions were
performed in assay buffer (50 mM HEPES, 100 mM KCl, 0.001% (v/v) Tween 20,
0.05% (w/v) bovine serum albumin, 200 μM TCEP, pH 7.4) and followed for
fluorogenic release of 7-amino-4-methylcoumarin from substrate upon deacetylase
and trypsin enzymatic activity. Trypsin was present at a final concentration of 50
nM (Worthington Biochemical Corporation). Fluorescence measurements were
obtained approximately every 5 min using a multilabel plate reader and plate
stacker (Envision, Perkin-Elmer). Data were analyzed on a plate-by-plate basis for
the linear range of fluorescence over time. The first derivative of data obtained
from the plate capture corresponding to the mid-linear range was imported into
analytical software (Spotfire DecisionSite and GraphPad Prism). Replicate experi-
mental data from incubations with inhibitor were normalized to DMSO controls.
HDAC1 inhibition assay. HDAC1 inhibitory activity was determined for each
compound using the Fluorogenic HDAC1 assay kit available from BPS Bioscience
(50061). Minor deviations from the manufacturer’s instructions were employed
and are described below. HDAC substrate 1 (50032) was used instead of HDAC
substrate 3 (50037). HDAC substrate 1 consists of a tetrapeptide based on residues
379–382 (RHKK(Ac)) of the tumor suppressor protein P53, a known HDAC
substrate. The peptide contains a fluorescent reporter that is activated after dea-
cetylation by the addition of Developer (50030). Reactions were carried out in 96-
well plates (Nunc low binding, black microtiter plates) with compounds being
screened in 10 dose IC50 format using 3-fold serial dilutions. 50 µl reactions con-
taining HDAC assay buffer (50031), 0.1 mg ml−1 BSA, 20 µM HDAC substrate 1,
and varying concentrations of inhibitor were initiated by the addition of HDAC1
(final [HDAC1] = 2.86 nM) and incubated at 37 °C for 30 min. After incubation,
the reactions were quenched by the addition of Developer and incubated at room
temperature for 15 min. Fluorescence was determined using a BioTek Instruments
Synergy HT plate reader with excitation at 360 nm and emission at 460 nm.
Inhibitor stocks were prepared in 20% DMSO/water by 3-fold serial dilution (final
concentration of DMSO in each reaction was 2%). Control experiments were run
to account for intrinsic compound fluorescence/fluorescence suppression. Fluor-
escence was normalized to the vehicle control, converted to percent activity, and
plotted against inhibitor concentration to generate 10-dose IC50 curves. To account
for slow, tight-binding inhibitors, all components of the reaction except for the
substrate were mixed in the 96-well plate and incubated at room temperature for
10 min. Then, the reaction was initiated by the addition of substrate and fluores-
cence was monitored as previously described. Data are representative of at least
three independent experiments.
Protein complex HDAC inhibition assay. Inhibition of CoREST complex HDAC
activity was determined using the same assay kit described in the HDAC1 inhi-
bition assay with minor differences. Reactions were carried out for 10 min using 50
µM HDAC substrate 1 and a final concentration of 2 nM CoREST ternary complex
or 8 nM MiDAC ternary complex. Slow, tight-binding was also accounted for as
described for the HDAC1 inhibition assay. Data are representative of at least three
independent experiments.
CoREST complex (HDAC) jump dilution assay. The CoREST ternary complex
(0.5 µM, buffer: 25 mM Tris-HCl, 50 mM KCl, 0.5 mM TCEP, pH 7.5) was incu-
bated with the indicated inhibitor (5 µM, 2% DMSO, 100 µM inositol hexaki-
sphosphate) at 25 °C for 30 min prior to jump dilution40. The complex was then
diluted to a final concentration of 2 nM in HDAC assay buffer (BPS Bioscience,
50031) containing 200 µM HDAC substrate 1 (BPS Bioscience, 50032) and 0.1 mg
ml−1 BSA. 50 µl aliquots were quenched at 0, 5, 10, 20, 40, 120 min with an equal
volume of Developer (BPS Bioscience, 50030) and fluorescence was measured as
described in the HDAC1 inhibition assay.
Prolonged HDAC inhibition assay. To determine if dual inhibitors could main-
tain inhibition of protein complex HDAC activity after extensive dialysis, 0.5 µM
CoREST or MiDAC ternary complex was treated with 5 µM inhibitor for 30 min at
4 °C in 50 µl of 25 mM Tris–HCl, 50 mM KCl, 100 µM inositol hexakisphosphate,
and 0.5 mM TCEP, pH 7.5. After 30 min, the reactions were transferred to dialysis
cassettes (Slide-A-Lyzer® 10 K MWCO MINI Dialysis Device, Thermo Fisher
Scientific, Halethorpe, MD) and dialyzed against 1 L of buffer (25 mM Tris–HCl,
50 mM KCl, 0.5 mM TCEP, pH 7.4) three times for 2 h each time at 4 °C. Of note,
it is important to keep the sample volume level at the same level of the dialysate to
avoid reaction dilution. After 6 h dialysis, the reactions were transferred to 0.5 ml
Eppendorf tubes and the protein complex HDAC inhibition assay was carried out
with the dialyzed complex. Inhibitor stocks were prepared, as described for the
HDAC1 inhibition assay. Data are representative of at least two independent
experiments.
Nucleosome deacetylation assay. N-terminal histone H3 tail peptides containing
H3K9Ac modifications were prepared using SPPS (0.1 mmol) and ligated to
truncated, recombinant histone H3 via sortase ligation41. Semisynthetic histone H3
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was refolded with other core histones to form histone octamers followed by
nucleosome reconstitution via gradient dialysis in the presence of nucleosomal
DNA42, 43. The CoREST ternary complex (final [CoREST] = 100 nM) was pre-
treated with inhibitor at 25 °C for 30 min in 50 mM HEPES, pH 7.5, 100 mM KCl
and 0.2 mgml−1 BSA. Reactions were initiated by the addition of nucleosome
substrate (final [nucleosome] = 100 nM) with a final reaction volume of 50 µl. 10 µl
aliquots taken at 0 h, 1 h, and 2 h were quenched with 10 mM EDTA and 4x sample
loading buffer, resolved using 15% SDS–PAGE gels, and analyzed via Western blot.
Nitrocellulose membranes were blocked with 5% BSA in TBST and incubated
overnight with primary antibodies, either α-H3K9Ac (Abcam, ab4441, 1:5000) or
α-Total H3 (Abcam, ab1791, 1:10,000), at 4 °C. Membranes were then treated with
HRP-conjugated secondary antibody which was detected using ECL reagent
available from GE Healthcare. Data are representative of two independent
experiments.
LSD2 counterscreen. C-terminally His tagged lysine specific demethylase 2
(LSD2) was overexpressed in E. coli after which the cells were lysed using a French
press with cold buffer (280 mM NaCl, 5.4 mM KCl, 20 mM Na2HPO4, 3.6 mM
KH2PO4, 1.3 mM PMSF, 6.8 µg µl−1 DNase I, 10% (v/v) glycerol, pH 7.4, 1× Roche
Complete EDTA-free protease inhibitor). Lysate was clarified by centrifugation and
the target protein purified by nickel affinity chromatography7. Inhibitor potency
toward the LSD1 homolog, LSD2, was determined using a procedure similar to that
described for LSD1 above7, 28, 39. Briefly, 60 µl reactions containing 50 mM HEPES,
pH 7.5, 0.1 mM 4-AP, 1 mM DHBS, 100 µM diMeK4H31−21 substrate, 0.04 mgml
−1 (906 nM) HRP, and 20 µM inhibitor were initiated by the addition of LSD2 (final
[LSD2] = 430 nM). Absorbance measurements and data processing were carried
out as described for LSD1. Data are representative of at least two separate
experiments.
MAO A/B counterscreen. MAO A (M7316), MAO B (M7441), and the tyramine
substrate (T90344) were purchased from Sigma-Aldrich. MAO A (83.2 µM) and
MAO B (83.7 µM) were aliquoted and stored at −80 °C until use according to the
manufacturer’s instructions. MAO A was diluted 8-fold to 10.4 µM with 50 mM
HEPES, pH 7.4 immediately before use. The tyramine substrate was stored at −80 °
C as a 100 mM stock in DMSO and diluted to 0.8 mM (MAO A) and 0.5 mM
(MAO B) with water immediately before use. In total 100 µl reactions containing
50 mM HEPES, pH 7.5, 0.1 mM 4-AP, 1 mM DHBS, tyramine substrate ([tyr-
amine] = 200 µM for MAO A (Km = 29 µM, kcat = 93 min−1) and 125 µM for MAO
B (Km = 93 µM, kcat = 0.20 min−1) assays), 0.04 mgml−1 (906 nM) HRP, and vary-
ing concentrations of inhibitor were initiated by the addition of either MAO A or B
(final [MAO A] = 0.2 µM, final [MAO B] = 1.674 µM)7, 28. Inhibitor stocks were
prepared as before and absorbance measurements and data processing were carried
out as described for LSD1. Data reported represent at least two separate
experiments.
Cell Culture. Ten melanoma cell lines were obtained from Dr. Meenard Herlyn
(The Wistar Institute, Philadelphia, PA). SK-MEL-5 cells were obtained from Dr.
Levi A. Garraway (Dana-Farber Cancer Institute, Boston, MA). HPMs were pur-
chased from Life Technologies (Grand Island, NY). HCT116 and LSD1−/− HCT116
cells were obtained as a gift from Dr. Robert Casero Jr27 and LSD1 knockout was
confirmed by western blot (α-LSD1, Abcam, ab17721, 1:500). The human cuta-
neous squamous cell carcinoma (cSCC) cell lines were derived from moderately
differentiated primary tumors: cSCC-IC1 cells were isolated from a tumor on the
right temple of a 77-year-old male immunocompetent patient and cSCC-MET1
cells were obtained from a tumor on the dorsum of the left hand of a 55-year-old
male renal transplant recipient. Primary keratinocytes were purchased from ATCC
(Manassas, VA). All cell lines used were routinely checked for and found to be free
of mycoplasma contamination. Melanoma cell lines were cultured in Dulbecco’s
modified eagle medium (Invitrogen) supplemented with 10% fetal bovine serum, L-
glutamine (2 mM), and 1% penicillin/streptomycin. HPMs were cultured in
Medium 254 with human melanocyte growth supplements. HCT116 cells were
cultured in McCoy’s 5 A medium with L-glutamine purchased from Corning
(Iwakata & Grace modification, Corning, N.Y.) and supplemented with 10% fetal
bovine serum. cSCC cells were cultured in a nutrient mixture of Dulbecco’s
minimal essential medium with Ham’s F12 medium (3:1) supplemented with 10%
FBS, hydrocortisone, human insulin, mouse EGF, cholera toxin, apo-transferrin,
and lyothyronine (L4). Keratinocytes were cultured in Dermal Cell Basal Medium
and supplemented with bovine pituitary extract (0.4%), TGF-α (0.5 ng ml−1), L-
glutamine (6 mM), hydrocortisone (100 ng ml−1), insulin (5 mgml−1), epinephrine
(1 mM), and apo-transferrin (5 mgml−1) following guidelines from ATCC. All cell
lines were maintained in a 37 °C incubator at 5% CO2.
Cell treatment with compounds. Inhibitor stocks were prepared in DMSO and
diluted as necessary. Appropriate stock solutions were added to culture medium to
achieve the desired final concentrations. An equal amount of DMSO was used as a
vehicle control.
Western blot. Whole-cell lysate was prepared in 3D-RIPA buffer. Protein (20 µg)
was separated by 12% SDS–PAGE and transferred to a polyvinylidene difluoride
membrane. Membranes were blocked using 5% nonfat dry milk in PBS containing
0.05% Tween 20, and then incubated with primary antibody overnight at 4 °C.
HRP-conjugated secondary antibody was used and detected using the Pierce ECL
Western Blot Substrate. Antibodies were obtained from the following sources:
H3K9Ac (Abcam, ab32129, 1:1000), H3K4Me2 (Abcam, ab32356, 1:5000),
H3K4Me1 (Abcam, ab8895, 1:5000), H3K4Me3 (Abcam, ab8580, 1:5000),
H3K14Ac (Millipore, 07–353, 1:5000), H3K18Ac (Millipore, 07–354, 1:5000), LSD1
(Abcam, ab17721, 1:500), HDAC1 (Abcam, ab19845, 1:1000), total H3 (Cell Sig-
naling Technology, 4499 S, 1:1000 or Abcam, ab1791, 1:10,000), β-actin (Santa
Cruz Biotechnology, sc47778, 1:2000), CoREST1 (BD Transduction Laboratories,
612146, 1:500), SIN3A (Abcam, ab129087, 1:1000), HRP-conjugated secondary
antibodies (Santa Cruz Biotechnology, 1:5000 for β-actin blots, 1:2000 for all
others). Blots shown are representative of at least two independent experiments.
Uncropped versions of Western blots are provided in the Supporting Information
(Supplementary Figs. 32and 33).
Solid phase sandwich ELISA. PathScan Acetyl-Histone H3 (Lys9) and Di-Methyl-
Histone H3 (Lys4) Sandwich ELISA Kits (Cell signaling 7121 C and 7124 C) were
used to detect levels of acetyl-H3 Lys9 and Di-Methyl-H3 Lys4 in cells treated with
compounds. Briefly, after 24 h treatment, cells were lysed with 1× Cell Lysis Buffer
plus 1 mM PMSF. 5 µg of cell lysate prepared in 100 µl Assay Diluent was added to
each well which was pre-coated with total H3 antibody. After overnight incubation
at 4 °C, the wells were washed four times with 1× Washing Buffer. 100 µl recon-
stituted biotinylated acetyl-Histone H3 (Lys9) or di-methyl Histone H3 (Lys4)
antibodies were added to each well and incubated for 1 h at 37 °C. After four
washes, 100 µl reconstituted HRP-linked streptavidin was added and incubated for
30 min at 37 °C. Following four washes, 100 µl TMB Substrate was added. After a
10 min incubation at 37 °C, 100 µl Stop Solution was added and absorbance at 450
nm was read within 30 min on a SpectraMax microplate reader using the SoftMax
Pro software (Molecular Devices, Sunnyvale, CA). Data are representative of two
independent experiments with two technical replicates per experiment.
PicoGreen® cell proliferation assay. Cells were seeded in a 96-well plate and
treated with inhibitor at the indicated concentrations. Media was removed and
replaced with fresh media containing compound every 24 h. After 72 h incubation,
20 µl lysis buffer (10 mM Tris–HCl, 1 mM EDTA, 0.2% (v/v) Triton X-100) was
added to each well and the plate was shaken vigorously on an orbital shaker for 10
min. 70 µl TE buffer was subsequently added to each well and the plate was agitated
for 5 min. Then, 95 µl of sample solution from each well was transferred to a new
96-well, non-clear bottom plate (NUNC 236105 96 F) and to each well was added
95 µl 1× PicoGreen® solution (Life Technologies, P11496). The plate was then
agitated for 5 min in the dark after which fluorescence was measured using exci-
tation and emission wavelengths of 480 nm and 520 nm, respectively, using a
SpectraMax microplate reader. Data represent at least two independent experi-
ments with three technical replicates per experiment. Where p-values are reported,
the unpaired t test was used to determine significance.
[3H]Thymidine incorporation assays. Cells were seeded in 96-well plates
(Corning, Corning, NY) for 24 h prior to treatment. HCT116 cells were treated at
~70% confluency and then cultured for an additional 48 h. IC1 cells (5000 cells/
well), MET1 cells (2500 cells/well), and primary keratinocytes (3750 cells/well)
were treated as indicated and cultured for an additional 72 h. Six hours prior to
harvesting cells, 10 µl of a 0.1 mCi ml−1 [3H]thymidine (American Radiolabeled
Chemicals, St. Louis, MO) solution in media was added to each well. Cells were
harvested using a Filtermate Harvester (PerkinElmer, Waltham, MA) and radio-
activity was measured using a MicroBeta liquid scintillation counter (PerkinElmer,
Waltham, MA). Data represent three independent experiments with four technical
replicates per experiment. Where p-values are reported, the unpaired t test was
used to determine significance.
CoREST1 and SIN3A knockdown. shRNA clones targeting CoREST
(TRCN0000128570 and TRCN0000129660) or SIN3A (TRCN0000021774) were
obtained from the High Throughput Biology Center at Johns Hopkins University.
Lentiviral particles were produced in HEK293T cells using Lipofectamine® 2000
(Invitrogen) according to the manufacturer’s instructions and stored at −80 °C after
0.22 μm filtration. For lentiviral infection, WM983B cells were incubated with
CoREST shRNA, SIN3A shRNA, or scramble containing lentiviral particles
overnight. Cells were selected with puromycin 48 h after transduction to create
stable cell lines. CoREST knockdown was determined by quantitative RT–PCR and
confirmed by Western blot. shRNA sequences are provided as Supplementary
Table 7.
Whole genome microarray. WM983B melanoma cells were treated for 24 h with
2.5 µM corin, MS-275, or DMSO as a control. RNA was isolated from cells fol-
lowing the manufacturer’s instructions and cleaned using RNeasy Plus Mini kit
(Qiagen Inc.). The isolated RNA was hybridized to the Affymetrix Human Gene
2.0 ST Array. Gene expression levels were analyzed using Affymetrix Human Gene
2.0 ST arrays at the Johns Hopkins Microarray Core Laboratory, including quality
control for extracted total RNA samples. Experiments were performed according to
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the manufacturer’s recommended protocols. In brief, the total extracted RNA was
converted into cDNA, amplified, purified, and biotin labeled. Labeled cDNA was
hybridized to HuGene2.0_ST array and was scanned using Affymetrix GeneChip
scanner 3000 with G7 upgrade (Affymetrix GeneChip Expression Analysis Tech-
nical Manual, Affymetrix, Santa Clara, CA). Data are representative of three
independent experiments.
Microarray data analysis. We extracted raw gene expression data, Affymetrix
exon CEL files, and RMA (Robust Multi-array Average)44, 45 and normalized them
using Partek Genomics Suite v6.6 analytic platform (Partek Inc., St. Louis, MO).
We converted the replicate cell samples’ gene expression values to log2 notation
and then compared the corresponding corin and MS-275 samples using a one-way
ANOVA model. We visualized the ANOVA results of this comparison as volcano
plots by using the Spotfire DecisionSite platform (TIBCO Software Inc., Palo Alto,
CA). We then performed further functional and pathway analyses to illuminate
underlying biologic mechanisms. Since the log2 fold changes (log ratios) of the
arrays’ 38,598 gene-annotated transcripts presented a normal distribution, their SD
(standard deviation) from the mean of no change was used to set the threshold for
highly up- and down-regulated genes that were used in pathway analysis. The set of
all ANOVA results was exported from Partek to the QIAGEN Ingenuity Pathway
Analysis platform (Qiagen Inc., Valencia, CA), where those genes showing greater
than 2 SD change up or down were compared to the universe of all the array’s
genes. This 2 SD value corresponds to a linear expression fold change of ~1.952
and comprised 1843 unique genes. Ingenuity software used the Fisher exact test to
identify biological functions that were statistically enriched for 2 SD differentially
expressed genes above what would be expected at random.
Quantitative real time-PCR. RNA was isolated from primary human melanocytes
and melanoma cells following the manufacturer’s instructions and cleaned using
the RNeasy Mini kit (Qiagen Inc.). In total 1 µg of RNA was reverse transcribed
using SuperScript® III First-Strand Synthesis System kit (Invitrogen). Real-time
quantitative PCR was performed for 40 cycles of 15 s at 95 °C and 30 s at 60 °C,
using the Step One Plus Real-time PCR system (Applied Biosystems). Data
represent two independent experiments with three technical replicates per
experiment. The data was calculated using the delta (delta Ct) method. Where p-
values are reported, the unpaired t test was used to determine significance. Tran-
scripts were amplified using the primers listed in Supplementary Table 8.
Chromatin immunoprecipitation assay (ChIP-PCR). WM983B cells (10 × 106)
were crosslinked in 1% formaldehyde for 7 min and lysed in cell lysis buffer (5 mM
HEPES, 85 mM KCl, 0.5% NP-40, 1× protease inhibitor cocktail (Sigma), 1×
phosphatase inhibitor cocktail (Sigma)) on ice for 20 min46. The nuclei were lysed
in buffer containing 50 mM Tris–HCl, pH 8, 10 mM EDTA, 1% SDS and then
chromatin was fragmented using the Bioruptor (Diagenode) sonicator to obtain an
average size of 250–300 base pairs. Chromatin concentration was measured by its
absorbance at 260 nm in the Nanodrop (1 unit ml−1 of chromatin corresponds to
OD260 = 1) and diluted 1:10 with dilution buffer (165 mM NaCl, 0.01% SDS, 1.1%
Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl, pH 8.0). 1 unit of chromatin was
immunoprecipitated by protein A magnetic beads (Dynabeads, Invitrogen) after
incubation with antibodies specific for HDAC1 (Abcam, ab19845, 1:1000) and
LSD1 (Abcam, ab17721, 1:500). Normal goat IgG and non-antibody treated
samples were used as negative controls. Following overnight immunoprecipitation,
beads were washed twice consecutively with each of the following buffers: Lio-B
(50 mM HEPES, pH 8.0, 140 mM NaCl, 1% Triton X-100, 0.1% sodium deox-
ycholate, 1 mM EDTA), Hio-B (50 mM HEPES, pH 8.0, 500 mM NaCl, 1% Triton
X-100, 0.1% sodium deoxycholate, 1 mM EDTA), LiCl (10 mM Tris–HCl, 250 mM
LiCl, 0.5% NP−40, 0.5% sodium deoxycholate, 1 mM EDTA) and TE (10 mM
Tris–HCl, pH 8.0, 1 mM EDTA). Immunoprecipitated chromatin and input DNA
were reverse crosslinked in elution buffer (50 mM Tris–HCl, 10 mM EDTA, 1%
SDS) in the presence of proteinase K (50 μg ml−1) by shaking (1300 RPM) at 68 °C
for 5 h. DNA was purified using phenol-chloroform and precipitated in ethanol at
−20 °C. DNA pellets were dissolved in 200 μL of ddH2O. The relevant primers are
listed in Supplementary Table 9.
Plasma stability studies. Drug-free (blank) human plasma originated from Bio-
logical Specialty Corp. (Colmar, PA, USA). Plasma studies were conducted in
human plasma and 500 ng ml−1 of corin in a final volume of 500 µl. Incubations
were performed in duplicate in glass tubes maintained at 37 °C in a shaker bath.
Stability studies were terminated immediately or after 0.5 or 1 h by taking 100 µl of
the plasma and adding 1 ml of acetonitrile, followed by vortex-mixing then cen-
trifugation for 10 min at 1430xg. A 100 µl aliquot of the supernatant was vortex-
mixed with 500 µl water prior to injection onto the UItra Performance LC (UPLC)
instrument for analysis using a temperature-controlled autosampling device
operating at 5 °C.
Microsomal stability studies. Human and mouse liver microsomes and the
NADPH regenerating systems were used to characterize the stability and meta-
bolism of corin that were purchased from Corning Life Sciences (Tewsbury, MA)
and BD Gentest Product and Services (Woburn, MA). Metabolism studies were
conducted in a 0.5 M sodium-potassium phosphate buffer (pH 7.4) containing 20
mgml−1 of either human or mouse liver microsomes, an NADPH-generating
system, and 10 mM of corin in a final volume of 500 µl. Negative controls were
performed without an NADPH-generating system to control for native enzyme
activities. Incubations were performed in duplicate in glass tubes maintained at 37 °
C in a shaker bath. The microsomal metabolism was terminated immediately or
after 0.5 or 1 h by taking 20 µl of the microsome mixture and adding 1 ml of
acetonitrile, followed by vortex-mixing then centrifugation for 10 min at 1430×g. A
10 µl aliquot of the supernatant was injected onto the UPLC instrument for qua-
litative analysis using a temperature-controlled autosampling device operating at 5
°C.
LCMS analysis. Chromatographic analysis was performed using a Waters
AcquityTM UItra Performance UPLC. Separation of the analyte from potentially
interfering material and metabolites was achieved at ambient temperature using
Waters Cortecs column (50 × 2.1 mm, L x I.D.) with a 2.7 µm particle size. (Mil-
ford, MA). The mobile phase used for the chromatographic separation was com-
posed of 0.1% (v/v) formic acid in water (mobile phase A) and 0.1% (v/v) formic
acid in methanol (mobile phase B) with a flow rate of 0.3 ml min−1. The initial
mobile phase composition was 90% mobile phase A and 10% mobile phase B. From
0.5 to 6.0 min, mobile phase B was increased linearly from 10 to 100% and
maintained until 7.0 min. From 7.0 to 7.1 min, the gradient decreased to 10%
mobile phase B and the conditions were maintained until 8 min to re-equilibrate
the column for the next injection. The column effluent was monitored using an AB
Sciex 5500 triple-quadruple mass-spectrometric detector. The instrument was
equipped with an electrospray interface, operated in positive mode and controlled
by the Analyst v1.6 software. For the stability study, the mass spectrometer was
programmed to monitor an MRM transition 429.1 → 394.0 for corin. Results were
assessed qualitatively comparing the average area ratio of corin at 0 h to the area
ratio at 0.5 h and 1 h for both mouse and human liver microsomes or plasma.
SK-MEL-5 melanoma xenograft. All animal studies were conducted in the Animal
Facility at Shanghai Bioduro Co. in accordance with Bioduro Institutional Animal
Care and Use Committee Guidance.
For the toxicity study, 6 Balb/c nude mice were randomly divided into two
groups: vehicle and corin (n = 3 animals per group). Animals were given vehicle
(5% DMSO/H2O) or corin (30 mg kg−1 at 10 ml kg−1) by intraperitoneal injection
(IP) once a day. Animal body weights were measured daily and clinical
observations were recorded daily for 10 days. Clinical observations include
appearance observation (hair coat, discharges, injury, lesion and eye) and behavior/
condition observation (gait, activity, nervous system, respiration and feces).
For the SK-MEL-5 xenograft studies, six to eight-week old female Balb/C nude
mice were purchased from Lingchang (Shanghai, China) and allowed to acclimate
for 1 week prior to beginning the experiment. For each animal, SK-MEL-5 (6 × 106)
cells in 150 µl growth media mixed with 50% matri-gel (BD, USA) were injected
into the subcutaneous tissue of the flank29, 47. When xenograft size reached an
approximate volume of 150 mm3, the 20 mice were randomized into 10 mice per
group with the average tumor volume distributed equally between groups (vehicle:
avg. initial mouse body weight was 18.0± 0.3 g, avg. tumor volume was 150± 9
mm3; corin: avg. initial mouse body weight was 18.3 ± 0.2 g, avg. initial tumor
volume was 151± 7 mm3). Vehicle control (5% DMSO/H2O) and corin (30 mg kg
−1) were administered at 10 ml kg−1 by IP once a day. Of note, a third arm also
containing 10 animals (avg. initial body weight was 18.4± 0.3 g, avg. initial tumor
volume was 151± 7 mm3) was included to evaluate MS-275 (30 mg kg−1) head to
head with corin. However, six of the ten animals died within one week of initiating
the study leading to early termination of this arm for ethical reasons. The mice
were maintained in a pathogen-free environment with free access to food and
water. Body weight and tumor volume were measured twice a week. Tumor size
was measured with linear calipers and calculated using the formula: ((length in
millimeters × (width in millimeters)2)/2). The mice were sacrificed after 4 weeks
and tumor weights were measured. Three animals from each treatment group were
chosen at random for follow up blood work. Where p-values are reported, the
unpaired t test was used to determine significance.
Xenograft tumor sample processing and immunohistochemistry. After sacri-
ficing the mice, tumors were removed and post-fixed in 3.7% formaldehyde. Serial
sections 5 μm thick were cut from the formalin fixed, paraffin embedded tissue
blocks, floated onto charged glass slides (Super-Frost Plus, Fisher Scientific), and
dried overnight at 60 °C. Sections were deparaffinized and hydrated using graded
concentrations of ethanol to deionized water prior to immunohistochemistry.
Tumor sections were blocked in serum (5% serum in PBS-T (0.5% TritonX-100 in
PBS)), and then incubated overnight at 4 °C in rabbit anti-Ki67 (Abcam, ab15580,
1:500). Sections were then incubated with fluorescence-conjugated (FITC) goat
anti-rabbit secondary antibody for 1 h at room temperature, washed with PBS, and
mounted using VECTASHIELD mounting medium (Vector Laboratories).
Data availability. Microarray data have been deposited in the NCBI GEO database
with accession number GSE87289. The data that support this study are available as
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Supplementary Data 1. The additional data that support the findings of this study
are available from the corresponding authors upon request.
Received: 9 October 2017 Accepted: 14 November 2017
References
1. Dawson, M. A. & Kouzarides, T. Cancer epigenetics: from mechanism to
therapy. Cell 150, 12–27 (2012).
2. Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K. & Schapira, M. Epigenetic
protein families: a new frontier for drug discovery. Nat. Rev. Drug. Discov. 11,
384–400 (2012).
3. Falkenberg, K. J. & Johnstone, R. W. Histone deacetylases and their inhibitors
in cancer, neurological diseases and immune disorders. Nat. Rev. Drug. Discov.
13, 673–691 (2014).
4. Itoh, T. et al. Structural and functional characterization of a cell cycle associated
HDAC1/2 complex reveals the structural basis for complex assembly and
nucleosome targeting. Nucleic Acids Res. 43, 2033–2044 (2015).
5. Laugesen, A. & Helin, K. Chromatin repressive complexes in stem cells,
development, and cancer. Cell Stem. Cell 14, 735–751 (2014).
6. Mohammad, H. P. et al. A DNA hypomethylation signature predicts antitumor
activity of LSD1 inhibitors in SCLC. Cancer Cell. 28, 57–69 (2015).
7. Prusevich, P. et al. A selective phenelzine analogue inhibitor of histone
demethylase LSD1. ACS Chem. Biol. 9, 1284–1293 (2014).
8. Binda, C. et al. Biochemical, structural, and biological evaluation of
tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and
LSD2. J. Am. Chem. Soc. 132, 6827–6833 (2010).
9. Mimasu, S. et al. Structurally designed trans-2-phenylcyclopropylamine
derivatives potently inhibit histone demethylase LSD1/KDM1. Biochemistry 49,
6494–6503 (2010).
10. Culhane, J. C., Wang, D., Yen, P. M. & Cole, P. A. Comparative analysis of
small molecules and histone substrate analogues as LSD1 lysine demethylase
inhibitors. J. Am. Chem. Soc. 132, 3164–3176 (2010).
11. Hayward, D. & Cole, P. A. LSD1 histone demethylase assays and inhibition.
Method. Enzymol. 573, 261–278 (2016).
12. Culhane, J. C. & Cole, P. A. LSD1 and the chemistry of histone demethylation.
Curr. Opin. Chem. Biol. 11, 561–568 (2007).
13. Inui, K. et al. Stepwise assembly of functional C-terminal REST/NRSF
transcriptional repressor complexes as a drug target. Protein Sci. 26, 997–1011
(2017).
14. Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and
computational approaches to estimate solubility and permeability in drug
discovery and development settings. Adv. Drug. Deliv. Rev. 46, 3–26 (2001).
15. Breslow, R. et al. Potent cytodifferentiating agents related to
hexamethylenebisacetamide. Proc. Natl Acad. Sci. USA 88, 5542–5546 (1991).
16. Bradner, J. E. et al. Chemical phylogenetics of histone deacetylases. Nat. Chem.
Biol. 6, 238–243 (2010).
17. Beckers, T. et al. Distinct pharmacological properties of second generation
HDAC inhibitors with the benzamide or hydroxamate head group. Int. J.
Cancer 121, 1138–1148 (2007).
18. Erikson, J. M. & Prough, R. A. Oxidative metabolism of some hydrazine
derivatives by rat liver and lung tissue fractions. J. Biochem. Toxicol. 1, 41–52
(1986).
19. Portolano, N. et al. Recombinant protein expression for structural biology in
HEK 293F suspension cells: a novel and accessible approach. J. Vis. Exp. 92,
e51897 (2014).
20. Watson, P. J., Fairall, L., Santos, G. M. & Schwabe, J. W. Structure of HDAC3
bound to co-repressor and inositol tetraphosphate. Nature 481, 335–340
(2012).
21. Alley, M. C. et al. Feasibility of drug screening with panels of human tumor cell
lines using a microculture tetrazolium assay. Cancer Res. 48, 589–601 (1988).
22. Shoemaker, R. H. The NCI60 human tumour cell line anticancer drug screen.
Nat. Rev. Cancer 6, 813–823 (2006).
23. Zingg, D. et al. The epigenetic modifier EZH2 controls melanoma growth and
metastasis through silencing of distinct tumour suppressors. Nat. Commun. 6,
6051 (2015).
24. Johannessen, C. M. et al. A melanocyte lineage program confers resistance to
MAP kinase pathway inhibition. Nature 504, 138–142 (2013).
25. Huang, P. H. et al. Histone deacetylase inhibitors stimulate histone H3 lysine 4
methylation in part via transcriptional repression of histone H3 lysine 4
demethylases. Mol. Pharmacol. 79, 197–206 (2011).
26. Vasilatos, S. N. et al. Crosstalk between lysine-specific demethylase 1 (LSD1)
and histone deacetylases mediates antineoplsatic efficacy of HDAC inhibitors in
human breast cancer cells. Carcinogenesis 34, 1196–1207 (2013).
27. Jin, L. et al. Loss of LSD1 (lysine-specific demethylase 1) suppresses growth and
alters gene expression of human colon cancer cells in a p53- and DNMT1
(DNA methyltransferase 1)-independent manner. Biochem. J. 449, 459–468
(2013).
28. Forneris, F., Binda, C., Vanoni, M. A., Battaglioli, E. & Mattevi, A. Human
histone demethylase LSD1 reads the histone code. J. Biol. Chem. 16,
41360–41365 (2005).
29. Li, R. et al. Long non-coding RNA BANCR promotes proliferation in malignant
melanoma by regulating MAPK pathway activation. PLoS ONE 9, e100893
(2014).
30. Al-Lazikani, B., Banerji, U. & Workman, P. Combinatorial drug therapy for
cancer in the post-genomic era. Nat. Biotechnol. 30, 679–692 (2012).
31. Brown, R., Curry, E., Magnani, L., Wilhelm-Benartzi, C. S. & Borley, J. Poised
epigenetic states and acquired drug resistance in cancer. Nat. Rev. Cancer 14,
747–753 (2014).
32. Oronsky, B., Oronsky, N., Knox, S., Fanger, G. & Scicinski, J. Episensitization:
therapeutic tumor resensitization by epigenetic agents: a review and
reassessment. Anticancer Agents Med. Chem. 14, 1121–1127 (2014).
33. Apsel, B. et al. Targeted polypharmacology: discovery of dual inhibitors of
tyrosine and phosphoinositide kinases. Nat. Chem. Biol. 4, 691–699 (2008).
34. Martin, M. P., Olesen, S. H., Georg, G. I. & Schonbrunn, E. Cyclin-dependent
kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of
bromodomains. ACS Chem. Biol. 8, 2360–2365 (2013).
35. Bostrom, J. et al. Variants of the antibody herceptin that interact with HER2
and VEGF at the antigen binding site. Science 323, 1610–1614 (2009).
36. Yu, M., Magalhaes, M. L., Cook, P. F. & Blanchard, J. S. Bisubstrate inhibition:
theory and application to N-acetyltransferases. Biochemistry 45, 14788–14794
(2006).
37. Duan, Y. C. et al. Design and synthesis of tranylcypromine derivatives as novel
LSD1/HDACs dual inhibitors for cancer treatment. Eur. J. Med. Chem. 140,
392–402 (2017).
38. Copeland, R. A. The drug-target residence time model: a 10-year retrospective.
Nat. Rev. Drug. Discov. 15, 87–95 (2016).
39. Szewczuk, L. M. et al. Mechanistic analysis of a suicide inactivator of histone
demethylase LSD1. Biochemistry 46, 6892–6902 (2007).
40. Copeland, R. A., Basavapathruni, A., Moyer, M. & Scott, M. P. Impact of
enzyme concentration and residence time on apparent activity recovery in
jump dilution analysis. Anal. Biochem. 416, 206–210 (2011).
41. Piotukh, K. et al. Directed evolution of sortase a mutants with altered substrate
selectivity profiles. J. Am. Chem. Soc. 133, 17536–17539 (2011).
42. Luger, K., Rechsteiner, T. J. & Richmond, T. J. Preparation of nucleosome
core particle from recombinant histones. Method. Enzymol. 304, 3–19
(1999).
43. Dyer, P. N. et al. Reconstitution of nucleosome core particles from recombinant
histones and DNA. Method. Enzymol. 375, 23–44 (2004).
44. Bolstad, B. M., Irizarry, R. A., Astrand, M. & Speed, T. P. A comparison of
normalization methods for high density oligonucleotide array data based on
variance and bias. Bioinformatics 19, 185–193 (2003).
45. Irizarry, R. A. et al. Exploration, normalization, and summaries of high density
oligonucleotide array probe level data. Biostatistics 4, 249–264 (2003).
46. Yan, G. et al. Selective inhibition of p300 HAT blocks cell cycle progression,
induces cellular senescence, and inhibits the DNA damage response in
melanoma cells. J. Invest. Dermatol. 133, 2444–2452 (2013).
47. Yamanaka, K. et al. Antitumor activity of YM155, a selective small-molecule
survivin suppressant, alone and in combination with docetaxel in human
malignant melanoma models. Clin. Cancer Res. 17, 5423–5431 (2011).
Acknowledgements
We thank the NIH, the FAMRI foundation, the V foundation, Rete Ematologica Lom-
barda (FRRB-Regione Lombardia), and the Italian Association for Cancer Research
(IG15208 and IG19162) for financial support. This work was supported by PRIN 2016
(prot. 20152TE5PK) (A.M.), NIH (R01GM114306) (A.M.), and the EMBO ALTF 261-
2011 (A.V.G.) funds. J.W.R.S. is a Wellcome Trust Senior Investigator (grant WT100237)
and Royal Society Wolfson Research Merit Award Holder. He is also supported by a
Biotechnology and Biological Sciences Research Council Project Grant BB/J009598/1 as
well as funds from 4SC. A.D.-K. is supported by a program award from Cancer Research
UK (C20953/A18644), a Biotechnology and Biological Sciences Research Council Project
Grant BB/L01923X/1, and a British Skin Foundation Project Grant 7015. A.E. was a
Kagome Visiting Scholar. We thank Xiaowen Yang and Peter Watson for help with the
protein expression and purification. We thank R. Casero for the HCT116 LSD1 knockout
cells and D. Meyers, C. Talbot, and J.W. Labonte for helpful advice in regard to synthetic
strategy, microarray data analysis, and computational modeling, respectively.
Author contributions
J.K., J.D., A.G., and S.V. designed and synthesized the dual inhibitors with contributions
from P.P., A.M., and P.C. J.K., A.G., D.H., N.A., Mi.W., and J.R. carried out the bio-
chemical characterization. Y.S. and J.S. established construct boundaries and protocols to
express, purify, and characterize a stable CoREST ternary complex in mammalian cells.
Y.S., D.H., and Mi.W. expressed and purified the CoREST ternary complex for enzyme
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-02242-4
12 NATURE COMMUNICATIONS | 8:  53 |DOI: 10.1038/s41467-017-02242-4 |www.nature.com/naturecommunications
assays. L.F. and C.M. expressed and purified the MiDAC complex. J.J. and S.RB. modeled
the corin bound CoREST complex. M.W. performed analyses of compounds in mela-
noma cell lines. M.W. and H.J.C. performed analyses of immunostaining and molecular
studies on melanoma xenograft tissues. M.W. performed gene silencing experiments for
CoREST and related epigenetic modifying genes in melanoma cell lines and all associated
analyses with the assistance of E.K. and H.R. M.W., J.K., and N.A. performed microarray
studies and analyses with the assistance of B.R. M.W. performed ChIP studies and
analyses with the assistance of E.K. and I.P. J.K., A.G., E.K., H.R, and A.E. performed
additional cell-based work with design contributions from A.D.-K., W.H., B.R., R.A., and
P.C. C.P. provided the SCC cell lines. N.M.A. carried out the drug stability studies with
contributions from M.R. Y.H. and M.W. carried out mouse xenograft studies with the
assistance of B.R. and I.P. Data analysis was supervised by A.D.-K., J.G., J.B., J.S., A.M., R.
A., and P.C. J.K. and P.C. drafted the manuscript. All authors were involved in the
experimental design, data interpretation, and manuscript editing.
Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-
017-02242-4.
Competing interests: The chemical material presented is the subject of provisional
patent application WO 2015/134973 titled “A Selective Phenelzine Analog Inhibitor of
Histone Demethylase LSD1”.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2017
Jay H. Kalin#1,2, Muzhou Wu3, Andrea V. Gomez4, Yun Song5, Jayanta Das2, Dawn Hayward2, Nkosi Adejola2,
Mingxuan Wu1,2, Izabela Panova3, Hye Jin Chung3, Edward Kim3, Holly J. Roberts 3, Justin M. Roberts 6,
Polina Prusevich2, Jeliazko R. Jeliazkov7, Shourya S. Roy Burman8, Louise Fairall5, Charles Milano5,
Abdulkerim Eroglu2, Charlotte M. Proby9, Albena T. Dinkova-Kostova2,9, Wayne W. Hancock10,
Jeffrey J. Gray 7,8,11, James E. Bradner 6, Sergio Valente12, Antonello Mai12, Nicole M. Anders11,
Michelle A. Rudek11, Yong Hu13, Byungwoo Ryu3, John W.R. Schwabe5, Andrea Mattevi 4
Rhoda M. Alani3 & Philip A. Cole1,2
1Division of Genetics, Departments of Medicine and Biological Chemistry and Molecular Pharmacology, Harvard Medical School and Brigham and
Women’s Hospital, Boston, MA 02115, USA. 2Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine,
Baltimore, MD 21205, USA. 3Department of Dermatology, Boston University School of Medicine, Boston, MA 02118, USA. 4Department of Biology
and Biotechnology, University of Pavia, 27100 Pavia, Italy. 5Department of Molecular and Cell Biology, University of Leicester, Leicester, LE1 9HN,
UK. 6Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. 7Program in Molecular Biophysics, Johns Hopkins
University, Baltimore, MD 21218, USA. 8Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD 21218,
USA. 9Division of Cancer Research, Jacqui Wood Cancer Centre, University of Dundee, Dundee, DD1 9SY, UK. 10Department of Pathology and
Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA. 11Sidney Kimmel Comprehensive Cancer Center,
Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. 12Pasteur Institute, Cenci-Bolognetti Foundation, Department of Drug
Chemistry and Technologies, Sapienza University of Rome, 00185 Rome, Italy. 13Department of Oncology, BioDuro LLC, Shanghai, 200131, China.
Jay H. Kalin, Muzhou Wu, Andrea V. Gomez, and Yun Song contributed equally to this work. John W.R. Schwabe, Andrea Mattevi, Rhoda M. Alani,
and Philip A. Cole jointly supervised the work.
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-02242-4 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:53 |DOI: 10.1038/s41467-017-02242-4 |www.nature.com/naturecommunications 13
